Saladax Develops First-Ever Rapid Test for an Antipsychotic Drug Using a Single Drop of Blood to Aid Psychiatrists in the Treatment of Schizophrenia
5.9.2019 16:30:00 EEST | Business Wire | Press release
Saladax Biomedical today announced that its MyCare Insite Clozapine Test is now CE marked for use on the MyCare Insite. The MyCare Insite Clozapine Test is the first and only rapid point-of-care test CE marked to aid mental health professionals in the treatment and monitoring of patients with schizophrenia.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190905005085/en/
The MyCare Insite Clozapine Test delivers accurate and precise clozapine blood levels comparable to laboratory results. Psychiatrists need immediate information to make informed decisions during a patient visit. The MyCare Insite Clozapine Test addresses this unmet medical need by providing answers in only six minutes. Clinicians, in consultation with their patients, can use these results to make real-time adjustments to better manage their patients.
"Mental health professionals have very few tools to aid in patient treatment; as a result, patients are suffering. The MyCare Insite Clozapine Test provides clinicians a first of its kind device. The test is evidence of how Saladax is once again setting new standards for innovation in the treatment and monitoring of patients," said Dr. Salvatore Salamone, CEO and Founder of Saladax Biomedical. "We are changing psychiatry with a single drop of blood.”
ABOUT PSYCHOSIS
Psychosis is a condition that affects the way your brain processes information. It causes you to lose touch with reality. Psychotic disorders, like schizophrenia, involve psychosis that usually affects you for the first time in the late teen years or early adulthood. Young people are especially at risk, but doctors don’t know why.
ABOUT THE MyCARE INSITE CLOZAPINE TEST
The MyCare Insite Clozapine Test is intended for the in vitro quantitative measurement of clozapine in human capillary finger blood using the MyCare Insite.
ABOUT SALADAX
Founded in 2004, Saladax Biomedical, Inc. is a privately held company headquartered as an anchor tenant at Ben Franklin TechVentures® located on Lehigh University’s campus in Bethlehem, PA.
Saladax develops rapid blood tests for point-of-care and for laboratory analysers for use in psychiatry and oncology. The Saladax MyCare Psychiatry line provides drug levels for greater insight into patient adherence and possible causes of treatment failures. These tests enable psychiatrists to more accurately assess adherence and better adjust medication dosing. Saladax believes that truly personalized medicine can only exist when the right drug is taken at the right dose. Our diagnostic reagent kits are distributed worldwide and are pending approval in the United States. Saladax is ISO 13485:2016 certified.
For more information, visit Saladax.com or MyCareTests.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190905005085/en/
Contact information
Saladax Biomedical, Inc.
Salvatore Salamone, Ph.D., 610-419-6731
ssalamone@saladax.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NEURA Robotics Announces Record Series C of up to $1.4 Billion to Accelerate the World’s Leading Physical AI Platform10.6.2026 18:26:00 EEST | Press release
NEURA Robotics (“NEURA”), the pioneer in cognitive robotics and creator of the Neuraverse, today announced a landmark Series C financing with a total round size of up to $1.4 billion to accelerate its mission of building the world’s leading Physical AI platform. The financing brings together global leaders across AI, robotics, compute, manufacturing and industrial infrastructure, including Tether, Qualcomm Technologies, Inc., Amazon, NVIDIA, imec.xpand, Bosch, Schaeffler, European Investment Bank, Lingotto Horizon, InterAlpen Partners and others. NEURA is building a new category of AI infrastructure where cognitive robots continuously learn, collaborate and operate across real world environments through a shared intelligence ecosystem called the Neuraverse. Unlike traditional robotics companies focused on isolated machines or narrow industrial automation, NEURA combines robotics, AI, sensors, edge compute and large scale learning infrastructure into one unified platform architecture de
ees Europe: Green Hydrogen: Opportunities and Production Ramp Up10.6.2026 17:13:00 EEST | Press release
For the major economies, the transformation towards a climate-neutral industry is one of the central tasks for the coming decades. While the European Union has pledged climate neutrality by 2050, China’s goal is to be climate-neutral by 2060. Hydrogen is a key to transforming their manufacturing and energy industry. However, the actual market development is lagging behind these ambitious objectives: According to the Global Energy Report 2025, only 11 percent of hydrogen projects announced since the start of the decade are now in operation or have been secured by investment decisions. This is why ees Europe, Europe’s largest and most international exhibition for batteries and energy storage systems, is putting a spotlight on hydrogen. The newly aligned exhibition segment Hydrogen Dialogue Forum & Expo in hall B2 will be giving in-depth information about the opportunities for hydrogen technology, technological innovation, savings potential and ground-breaking projects from June 23–25. Th
Info-Tech Research Group Recognizes Laserfiche as a Champion in the 2026 Enterprise Content Management – Enterprise Emotional Footprint Report10.6.2026 17:00:00 EEST | Press release
Laserfiche has been named a Champion for the enterprise category in the Enterprise Content Management Emotional Footprint 2026 Report by Info-Tech Research Group. Laserfiche — the leading SaaS provider of intelligent content management — was recognized based on reviews provided by end users. Laserfiche was recognized as a Champion for delivering significant business value, continued product innovation, and strong customer experience. “We are honored to be named a Champion by Info-Tech Research Group, which we believe underscores our relationships with our customers and commitment to their long-term success,” said Thomas Phelps, CIO and SVP of corporate strategy at Laserfiche. “We are grateful to our customers for partnering with us as we support their needs for AI-driven information management solutions. Of the 285 customers who completed an Info-Tech survey this year, 99% said they plan to renew.” Info-Tech Research Group’s Emotional Footprint report quantifies the end-user experience
BTG Pactual TIG Acquires Jamestown’s Timberland Platform10.6.2026 16:30:00 EEST | Press release
BTG Pactual Timberland Investment Group (BTG Pactual TIG), one of the world’s largest timberland investment managers, today announced the acquisition of approximately 90,000 acres of U.S. timberland formerly managed by Jamestown, a global design-focused real estate investment and management firm. The Jamestown timberland platform will be integrated into BTG Pactual TIG’s core U.S. timberland strategy’s portfolio. The portfolio of high-quality timberland spans five U.S. states, including approximately 50,000 acres of pine timberland in Georgia and Alabama and approximately 40,000 acres of diversified hardwood timberland across Indiana, Pennsylvania, and New York. All properties are certified under the Sustainable Forestry Initiative (SFI). The acquisition increases BTG Pactual TIG’s core U.S. timberland strategy’s portfolio to more than 1.7 million acres. The firm manages 3.3 million acres globally. The transaction creates further opportunities for BTG Pactual TIG to scale positive cons
Capcom’s Dragon’s Dogma 2: Dark Arisen Scheduled to Launch on October 9, 2026!10.6.2026 16:00:00 EEST | Press release
Capcom Co., Ltd. (TOKYO:9697) today announced that Dragon’s Dogma 2: Dark Arisen, which includes an expansion for Dragon’s Dogma 2, is scheduled to be released on October 9, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260610422753/en/ Dragon's Dogma 2: Dark Arisen logo The Dragon’s Dogma series consists of action games in a fantasy setting where players adventure in an expansive open world of swords and magic. Since the release of the first game in 2012, the series garnered praise worldwide for gameplay features such as its “pawn” adventure companions who can carry out actions on their own, leading the series to over 14 million* units sold cumulatively. Dragon’s Dogma 2: Dark Arisen is a paid expansion title that adds a new story to Dragon’s Dogma 2, which was released in March 2024. Based on the wide range of feedback received following the release of the main game, this expansion is being developed to offer greate
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom